Wright Medical Group N.V. (WMGI)
(Delayed Data from NSDQ)
$29.93 USD
+0.29 (0.98%)
Updated May 3, 2019 04:00 PM ET
After-Market: $29.93 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.93 USD
+0.29 (0.98%)
Updated May 3, 2019 04:00 PM ET
After-Market: $29.93 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q4
by Zacks Equity Research
HealthEquity (HQY) witnesses strong HSA member growth in the fourth quarter of fiscal 2019.
Allscripts Partners With Opargo to Boost Practice Management
by Zacks Equity Research
Allscripts' (MDRX) partnership with Opargo is likely to improve scheduling capabilities and practice workflows of Allscripts Practice Management solution.
Veeva Systems (VEEV) Gains From Solid Results for Fiscal Q4
by Zacks Equity Research
Veeva Systems' (VEEV) broad spectrum of products include Veeva Vault, Veeva CRM, Veeva Network and Veeva OpenData.
Stryker Buys Israel-Based OrthoSpace, Strengthens MedSurg
by Zacks Equity Research
Strong international presence and an acquisition-driven strategy are likely to fortify Stryker's (SYK) footprint in the global MedTech space.
Zacks.com featured expert Kevin Matras highlights: Columbia Sportswear, Tactile Systems Technology, Wright Medical, Carbonite and Palo Alto Networks
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Columbia Sportswear, Tactile Systems Technology, Wright Medical, Carbonite and Palo Alto Networks
Allscripts Strengthens Strategic Relationship with Pulse8
by Zacks Equity Research
Pulse8 is likely to boost Allscripts' (MDRX) flagship platform Veradigm, and its existing health plan product suite that delivers pocket-friendly tools and services for health plan members.
Wright Medical Group (WMGI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Wright Medical (WMGI) delivered earnings and revenue surprises of 83.33% and 0.34%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Play Potential Earnings Beat With These 5 Top Stocks
by Sanghamitra Saha
These top-ranked stocks are likely to beat on the bottom line in their next release.
Here's Why Investors Should Retain McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) is well positioned for growth backed by strong business plans and robust surprise trend amid cutthroat competition in the near term.
Allscripts to Fortify Middle East Foothold With New Project
by Zacks Equity Research
Qatar-based Alfardan Group and Chicago-based Northwestern Medicine select Allscripts (MDRX) for the launch of a project in the Middle East.
Here's Why Investors Should Bet on Cooper Companies (COO) Now
by Zacks Equity Research
Cooper Companies (COO) maintains its leading position in the markets of specialty lenses. Further, the company exits first-quarter fiscal 2019 on a strong note.
Here's Why Investors Should Bet on Merit Medical (MMSI) Now
by Zacks Equity Research
Merit Medical's (MMSI) upbeat guidance for 2019 is indicative of the company's brighter prospects.
Baxter (BAX) Gets FDA Approval for Eptifibatide to Treat ACS
by Zacks Equity Research
Baxter's (BAX) Eptifibatide is a platelet aggregation inhibitor that prevents platelets-specialized blood cells clotting.
Here's Why You Should Invest in AngioDynamics Stock Now
by Zacks Equity Research
Expanding customer base of the NanoKnife platform is likely to fortify AngioDynamics' (ANGO) foothold in the Medical Instruments space.
Chemed Gains Ground on Solid VITAS & Roto-Rooter Businesses
by Zacks Equity Research
Chemed (CHE) witnesses solid revenue growth across key subsidiaries.
Wright Medical (WMGI) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Wright Medical's (WMGI) top-line growth in fourth-quarter 2018 can be attributed to solid performance by the Upper and the Lower Extremities segments.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina (ILMN) continues to gain on solid international business.
Integer Holdings' (ITGR) 2019 View Strong Despite Rivalry
by Zacks Equity Research
Integer Holdings (ITGR) holds a solid position in the MedTech space but is still exposed to competition.
Masimo and Saudi Arabia MOH Collaborate for CCHD Screening
by Zacks Equity Research
Studies have shown that Masimo's (MASI) SET pulse oximetry can improve CCHD screening, helping to save newborns.
Luminex Hurt By Segmental Sluggishness, Stiff Competition
by Zacks Equity Research
Luminex's (LMNX) dependence on its partners for revenue generation is a major problem.
Here's Why Investors Should Buy Surmodics (SRDX) Stock Now
by Zacks Equity Research
Surmodics' (SRDX) solid efforts to improve its research and development stature are likely to prove beneficial in the quarters ahead.
What's in the Cards for Genomic Health (GHDX) in Q4 Earnings?
by Zacks Equity Research
Genomic Health (GHDX) is expected to gain from higher Oncotype DX breast cancer test revenues in Q4.
Can Dental Growth Drive Henry Schein's (HSIC) Q4 Earnings?
by Zacks Equity Research
Henry Schein (HSIC) is well placed to gain from digitalization in the global dental market.
Here's What Will Give Shape to Medtronic's (MDT) Q3 Earnings
by Zacks Equity Research
Medtronic (MDT) is expected to maintain a decent market share in the core pacing backed by the continued uptake of Micra Transcatheter Pacing System in Q3.
Here's Why Investors Should Buy CONMED (CNMD) Stock Now
by Zacks Equity Research
CONMED's (CNMD) guidance for 2019 buoys optimism in the stock.